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Abstract 
Complete or partial loss of chromosome 7 is a 
recurrent cytogenetic abnormality that may be 
observed in both de novo and therapy-related 
hematopoietic disorders. It predominantly presents 
as monosomy 7 or deletion of the long arm of 
chromosome 7, often associated with an unfavorable 
prognosis. Deletions of the short arm of chromosome 
7, originated from either a terminal or an interstitial 
deletion are less frequent and their pathological 
significance is less well characterized. 
KEYWORDS 
Monosomy 7; 7p deletions; gene deletions; tumor 
suppressor genes. 
Identity 
del(7)(p11-15) Partial karyotypes showing deletions of the short arms of chromosome 7. Hybridization with 
Vysis D7S486 (7q31)/CEP 7 probe (Abbott moleculars, US) showing deletion of 7p proximal to chromosome 7 
centromere.  
Clinics and pathology 
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Disease 
Myeloid malignancies and acute lymphoblastic 
leukemia (ALL). 
Etiology 
Deletion of 7p as the sole abnormality occurs in 
disorders with myelodysplastic or 
myeloproliferative features and acute lymphoblastic 
leukemia, and may therefore affect early 
hematopoietic progenitor cells. 
Epidemiology 
Myeloproliferative disorders mainly: chronic 
myeloproliferative disorder in 9 (balanced sex 
ratio; 4 males and 5 females aged 53 to 79 
years old, median age 63 years) (Bernstein et 
al., 1980; CML Yunis et al., 1986; Obeid et al., 
1989; Palka et al., 1990; Rodjer et al., 1990; 
Ohyashiki et al., 1993; Pedersen-Bjergaard et 
al., 1993; Lezon-Geyda et al., 2001; 
Maciejewski et al., 2002) and AML in 10 
patients (4 males and 6 females, aged 0 to 80 
years, median age 0 years) (Bernstein et al., 
1984; Testa et al., 1985; Mecucci et al., 1989; 
Abruzzo et al., 1992; Veldman et al., 1997; 
Chessells et al., 2002; Babicka et al., 2007; 
Blink et al., 2012). Male prevalence and 
prevalence of T-cell phenotype and in ALL (6 
males and 2 females aged 3 to 50 years, 
median age 25 years) (Kaneko et al., 1989; 
Berger et al., 1990; Bernard et al., 2001; 
Berger et al., 2003; Douet-Guilbert et al., 
2004; Mullighan et al., 2009; Russell et al., 
2009; Safavi et al., 2015). 5 patients with 
myeloid malignancies had secondary disorders 
treated for a previous malignancy (Mecucci et 
al., 1989; Rodjer et al., 1990; Abruzzo et al., 
1992; Pedersen-Bjergaard et al., 1993). Three 
patients were Down syndrome patients (Table 
1).   
(Table 1).  
Chronic myeloproliferative disorders  
1 F/64 CMD 46,XX,del(7)(p11)  
2 M/71 RAEB 46,XY,del(7)(p11p22)  
3 F/62 CMMoL 46,XX,del(7)(p11)  
4 F/68 RAEB 46,XX,del(7)(p13)  
5 M/62 RA 45,XY,-10/46,XY,del(7)(p13p14)       multiple myeloma, chemotherapy 
6 F RA 46,XX,del(7)(p14)  
7 F/63 MDS 46,XX,del(7)(p11) 46,XX,-7,+21       multiple myeloma, chemotherapy 
8 M/76 MDS 46,XY,del(7)(p12p15)  
9 M/53 RA 47,XY,del(7)(p13p22) 
Acute myeloid leukemia 
10 M/7 AML-M2 46,XY,del(7)(p11)  
11 M/51 AML-M1 46,XY,del(7)(p1?5)  
12 F/20 AML-M4 46,XX,del(7)(p14 
13 M/47 AML-M2 46,XY,del(7)(p12p21)       Hodgkin disease, chemotherapy, radiotherapy 
14 F/80 AML-M4 46,XX,del(7)(p12p21)       polycythemia vera, chemotherapy, radiotherapy 
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15 F/11 AML 46,XX,del(7)(p12)       mature B-cell neoplasm, chemotherapy 
16 F/57 AML-M7 47,XX,del(7)(p?),+21c  
17 F/0 AML-M7 46,XX,del(7)(p15)  
18 M/55 AML-M0 46,XY,del(7)(p12)/46,idem,t(2;2)(q31;q35)  
19 F/1 AML 47,XX,del(7)(p11),+21c  
Acute lymphoblastic leukemia 
20 M/14 T-ALL 46,XY,del(7)(p15)  
21 M/25 T-ALL 46,XY,del(7)(p13p15)  
22 M/25 T-ALL 46,XY,del(7)(p13)  
23 M/29 T-ALL 46,XY,del(7)(p11p15)  
24 M/50 T-ALL 46,XY,del(7)(p12)  
25 F ALL 47,XX,del(7)(p13p15),+21c 
26 F/3 B-ALL 47-48,XX,+17,del(20),+21,inc/46,XX,del(7)(p11)  
27 M/30 T-ALL 46,XY,del(7)(p13)  
Abbreviations:  M, male; F, female; CMD, chronic myeloproliferative disorder; RAEB, refractory anemia with 
excess of blasts; MDS, myelodysplastic syndrome; CMMoL, chronic myelomonocytic leukemia; RA, refractory 
anemia; AML-M2, acute myeloblastic leukemia with maturation; AML-M1, acute myeloblastic leukemia without 
maturation; AML-M4, acute myelomonocytic leukemia; AML, acute myeloid leukemia; AML-M7, acute 
megakaryoblastic leukemia; AML-M5, acute monoblastic leukemia; AML-M0, acute myeloblastic leukemia with 
minimal differentiation, ALL, acute lymphoblastic leukemia/lymphoblastic lymphoma. 
1. Bernstein et al., 1980; 2. Yunis et al., 1986;  3. Obeid et al., 1989; 4. Palka et al., 1990. 5. Rodjer et al., 1990; 6. 
Ohyashiki et al., 1993; 7. Pedersen-Bjergaard et al., 1993; 8. Lezon et al., 2001; 9. Maciejewski et al., 2002; 10. 
Bernstein et al., 1984; 11. Testa et al., 1985; 12-14. Mecucci et al., 1989; 15. Abruzzo et al., 1992; 16. Veldman 
et al., 1997; 17. Chessells et al., 2002; 18. Babicka et al., 2007;  19. Blink et al., 2012; 20. Kaneko et al., 1989; 21. 
Berger et al., 1990; 22. Bernard et al., 2001; 23. Berger et al., 2003; 24. Douet-Guilbert et al., 2004; 25. Mullighan 
et al., 2009; 26. Russell et al., 2009; 27. Safavi et al., 2015. 
 
Cytogenetics 
Represents as interstitial (9 cases) or terminal 
deletion (18 patients) with various breakpoints. 
Prognosis 
Deletion of 7p, appears to confer increased risk of 
treatment failure and inferior outcome, same as it 
observed with monosomy 7 in myeloid 
malignancies. Similarly, event-free survival and 
survival for patients with monosomy 7 or del(7p), 
but not of patients with del(7q), were significantly 
worse in ALL patients than those lacking these 
abnormalities suggesting the critical region of loss 
may be on the p-arm (Mecucci et al., 1989; Heerema 
et al. 2004). 
Genes involved and 
proteins 
Germinal Mutations Deletions of the short arm of 
chromosome 7 that contains the GLI3 (GLI family 
zinc finger 3) gene at 7p14.1 are responsible for 
some cases of Greig cephalopolysyndactyly 
contiguous gene deletion syndrome, a disorder that 
affects development of the limbs, head, face that may 
be associated with intellectual disability. 
Chromosomal deletion or mutation within the 
TWIST1 (twist family bHLH transcription factor 1) 
gene at 7p21.1 is observed in Saethre-Chotzen 
syndrome associated with intellectual disability and 
developmental delay. 
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Chromosome 7p deletion is a recurrent cytogenetic 
abnormality that may be observed at initial 
presentation or may emerge during disease 
progression. Terminal or interstitial 7p deletions 
result in loss of the deleted material, supporting the 
existence of tumor-suppressor genes in that region. 
While no consistent region of loss was identified, 
these chromosomal deletions may contain areas 
harboring multiple functionally linked genes whose 
loss of function is thought to be the major event in 
disease initiation or progression. Most 7p losses 
involve large chromosomal regions, therefore it is 
likely that a cluster of cooperating tumor-suppressor 
genes collectively promote oncogenesis in dosage-
dependent manner. 
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